The clinical efficacy observation of VAD regimen in the treatment of newly diagn osed multiple myeloma
- VernacularTitle:VAD方案治疗初发的多发性骨髓瘤临床疗效观察
- Author:
Lan XU
;
Jieying HAN
;
Lu ZHONG
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
chemotherapy;
vincristine;
doxorubicin
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To evaluate the clinical efficacy of V AD regimen in the treatment of newly diagnosed stage III multiple myeloma (MM). Methods:26 patients with newly diagnosed stage Ⅲ multiple myel oma were treated with VAD regimen. VAD solution consisted of vincristine (VCR) , doxorubicin(ADR),dexamethasone (Dex).Three continuous treatments in one treatm ent course were considered evaluable.Evaluation included results of serum myelom a protein(M-protein); renal function; proteinuria of 24-hours; bone marrow ; per ipheral blood et al.The side reactions were recorded. The clinical efficacy eval uation was divide into complete response(CR),partial response(PR),minimal-respon se(MR), no change(NC) , plateau progression.Results:5 cases achieved CR(19.3%), 13 cases PR(50%),6 case s MR (23%), 2 cases no change (7.7%). Overall response rate was 92.3%, median su rvival duration was 7 to 84 months (29.6?17months). Conclusions:Achieved marked clinical efficacy with VAD agent in newly diagnosed stage III multiple myeloma. Especially,the patients with renal failure and serious clinical manifestation improved rapidly and significantly.
